PRODUCT SPECIFICATION

iLite® C5a Assay Ready Cells
REF: BM4075
For research use only. Not for use in diagnostic procedures.

DESCRIPTION

iLite® C5a Assay Ready Cells are human embryonic kidney HEK2931 cells
which have been genetically engineered and optimized to be responsive tohuman complement component 5a (C5a), resulting in a proportional expressionof Firefly Luciferase. The cells also contain the Renilla luciferase (RL) internal
standardization gene under the control of a constitutive promoter that renders
assay results independent of cell number and provides a means for correcting
for cytotoxic effects that may be encountered with some biological samples.

CONTENT>250 µL of Assay Ready Cells suspended in cryoprotective medium from Gibco(cat no 12648-010).

RECEIPT AND
STORAGE

Upon receipt confirm that adequate dry-ice is present, and the cells are frozen.
Immediately transfer to ultra-temperature storage. Cells should be stored atleast at -80 °C but preferably at lower temperature and are stable as supplied
until the expiry date shown. Cells should be diluted and plated immediately afterthawing.

BACKGROUNDC5a is a 74 amino acid small protein fragment of complement protein 5 (C5).
C5 is cleaved to C5a and C5b by C5 convertase enzymes as a result ofcomplement activation. Factors of the coagulation and fibrinolytic pathway arealso able to cleave C5 to C5a. (1) C5a is a highly potent anaphylatoxin andchemoattracting peptide, with the ability to increase blood vessel permeability,
stimulatation of cytokine release from myeloid cells, and expression of adhesion
molecules on endothelial cells. (2)Main pro-inflammatory effector functions are induced by C5a binding to a seventransmembrane G-protein-coupled receptor, C5aR1 (CD88). Rapidly aftercleavage of C5 into C5a and C5b, C5a is metabolized by carboxypeptidases
which removes the C-terminal arginine and forms C5a-desArg, a less potent
ligand of C5aR1. C5a can also bind to a second receptor, C5aR2 (C5L2 orGPR77), however the biological effects associated with C5a binding C5aR2 areless well understood, both anti-inflammatory and pro-inflammatory effects havebeen described in literature. The C5a receptors are expressed in a wide range
of cells and tissues, and the effect of C5a activation is dependent on the locationof the C5a receptors. (3, 4)
While the complement system is an important part of the innate immune defense
against pathogens, research has shown that excessive complement activation
including C5a-C5aR interaction plays a central role in several autoimmune andneurodegenerative disorders as well as in acute and chronic inflammatory
conditions. Given the strong evidence of a pathogenic role for C5a-C5aR inmany disorders both ligand and receptor are promising therapeutic targets.
Clinical studies of pharmacologic candidates inhibiting C5a and C5aR1 areongoing. (2,3,5)

1The HEK-293 cell line has been used under a license obtained from AdVec Inc.

Svar Life Science AB
Lundavägen 151

1P.O. Box 50117

info@svarlifescience.com

SE-212 24 Malmö

SE-202 11 Malmö+46 40 53 76 00

SwedenSwedenLABEL-DOC-0509, 4.0
Page 1/ 2

PRODUCT SPECIFICATIONAPPLICATION

The iLite® C5a Assay Ready Cells can be used for studies of C5a, receptor
C5aR1 and their interaction in test samples, including human serum.
Application Notes for the following assays are available:• Quantification of functional C5a (LABEL-DOC-0510)• Detection of C5aR inhibitory activity (LABEL-DOC-0511)

REFERENCES

1.
2.
3.
4.

5.

Manthey et al. Complement Component 5a (C5a). Int J Biochem Cell Biol.
2009 Nov;41(11):2114-7.
Woodruff et al. Inhibiting the C5–C5a receptor axis. Mol Immunol. 2011
Aug;48(14):1631-42.
P N Monk et al. Function, Structure and Therapeutic Potential ofComplement C5a Receptors. Br J Pharmacol 2007 Oct;152(4):429-48.
Colley et al. Structure and characterization of a high affinity C5amonoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.
MAbs. 2018 Jan;10(1):104-117.
Hawksworth et al. New concepts on the therapeutic control of complement
anaphylatoxin receptors. Mol Immunol. 2017 Sept;89:36-43.

SYMBOLS ON
LABELPRECAUTIONS

Lot number

Temperature limitation

Catalogue number

Biological risk

Use byManufacturer

For research use only. This product is intended for professional laboratory
research use only. The data and results originating from using the productshould not be used either in diagnostic procedures or in human therapeutic
applications.
iLite® C5a Assay Ready Cells are a stably transfected cell line of human origin
classified as a Class 1 Genetically Modified Microorganism. iLite® Assay ReadyCells should be handled in accordance with EU directive (2009/41/EC) anddisposed of in a licensed contained-use facility in accordance with theseregulations. When used in accordance with the manufacturer’s productspecification, the requirements of EC Directive 2009/41/EC on the containeduse of genetically modified microorganisms are deemed to have been met.
Residues of chemicals and preparations generally considered as biohazardous
waste should be inactivated prior to disposal by autoclaving or using bleach. Allsuch materials should be disposed of in accordance with established safety
procedures.

PROPRIETARYINFORMATION

Svar Life Science AB
Lundavägen 151

In accepting delivery of iLite® Assay Ready Cells the recipient agrees not to
sub-culture these cells, attempt to sub-culture them or to give them to a third
party, and only to use them directly in assays. iLite® cell-based products arecovered by patents which is the property of Svar Life Science AB and any
attempt to reproduce the delivered iLite® Assay Ready Cells is an infringementof these patents.

2P.O. Box 50117

info@svarlifescience.com

SE-212 24 Malmö

SE-202 11 Malmö+46 40 53 76 00

SwedenSwedenLABEL-DOC-0509, 4.0
Page 2/ 2